P. Fleck

发表

The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.

M. Taskinen, A. Tura, A. Mari, 2014, European journal of endocrinology.

alogliptin and pioglitazone combination therapy improves beta-cell function in patients with recent-onset type 2 diabetes ChaPTeR 6

M. Taskinen, A. Tura, A. Mari, 2013 .

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

R. DeFronzo, Q. Mekki, Craig A. Wilson, 2008, Diabetes Care.

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

R. Pratley, Q. Mekki, M. Kipnes, 2009, Diabetes, obesity & metabolism.

Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants

Q. Mekki, E. Wann, A. Karim, 2009, Journal of clinical pharmacology.

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.

Q. Mekki, E. Wann, A. Karim, 2010, International journal of clinical pharmacology and therapeutics.

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose‐ranging study

M. Samtani, M. E. Frustaci, M. Alba, 2021, Clinical obesity.

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

R. DeFronzo, C. Burant, R. Pratley, 2012, The Journal of clinical endocrinology and metabolism.

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy

Alfonso T. Perez, P. Berhanu, S. Demissie, 2006, Diabetes & vascular disease research.

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study

M. Taskinen, J. Cederholm, B. Eliasson, 2012, Diabetologia.

Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study

M. Nauck, Q. Mekki, P. Fleck, 2009, International journal of clinical practice.

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study

J. Rosenstock, P. Fleck, C. Wilson, 2013, Diabetes, obesity & metabolism.

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.

Q. Mekki, E. Wann, A. Karim, 2008, Clinical therapeutics.

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study

S. Del Prato, R. Camisasca, P. Fleck, 2014, Diabetes, obesity & metabolism.

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

J. Rosenstock, S. Inzucchi, J. Seufert, 2010, Diabetes Care.

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia

J. Rosenstock, J. Gross, Q. Mekki, 2009, Diabetes, obesity & metabolism.

ALOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES AFTER ACUTE CORONARY SYNDROMES: HEART FAILURE OUTCOMES AND CARDIOVASCULAR SAFETY IN HEART FAILURE PATIENTS

W. Cushman, C. Cannon, G. Bakris, 2014 .

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

W. Cushman, C. Cannon, G. Bakris, 2015, The Lancet.

Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus

S. Del Prato, P. Chaudhari, P. Fleck, 2016, Diabetes, obesity & metabolism.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Craig Wilson, Christopher P Cannon, Faiez Zannad, 2013, The New England journal of medicine.

Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

R. Pratley, Q. Mekki, Craig A. Wilson, 2009, Journal of the American Geriatrics Society.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

R. Pratley, J. Reusch, Q. Mekki, 2009, Current medical research and opinion.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

Q. Mekki, E. Wann, A. Karim, 2008, Clinical therapeutics.

A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes

M. Bron, Craig A. Wilson, P. Fleck, 2014, Diabetes Therapy.

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group study

E. Bosi, G. Ellis, P. Fleck, 2011, Diabetes, obesity & metabolism.

Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial

W. Cushman, C. Cannon, G. Bakris, 2014, Diabetes Care.

Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus

W. White, R. Pratley, V. Menon, 2013, Diabetes, obesity & metabolism.

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug‐naïve patients with type 2 diabetes: a randomized, double‐blind, 6‐month study

R. Pratley, P. Fleck, C. Wilson, 2014, Diabetes, obesity & metabolism.

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study

M. Samtani, M. E. Frustaci, M. Alba, 2021, Clinical obesity.

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study

J. Rosenstock, P. Fleck, C. Wilson, 2013, Diabetes, obesity & metabolism.

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

R. DeFronzo, R. Pratley, Q. Mekki, 2012, The Journal of clinical endocrinology and metabolism.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

R. Pratley, J. Reusch, Q. Mekki, 2009, Current medical research and opinion.

Q. Mekki, E. Wann, A. Karim, 2008, Clinical therapeutics.

E. Bosi, P. Fleck, C. Wilson, 2011, Diabetes, obesity & metabolism.